Targocid

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Teicoplanin 200mg;  

Available from:

sanofi-aventis new zealand limited

INN (International Name):

Teicoplanin 200 mg

Dosage:

200 mg

Pharmaceutical form:

Powder for injection with diluent

Composition:

Active: Teicoplanin 200mg   Excipient: Sodium chloride Sodium hydroxide Water for injection

Units in package:

Ampoule, glass, 1 x 3 mL, 3 mL

Class:

Prescription

Prescription type:

Prescription

Manufactured by:

Biochimica Del Salento S.p.A.

Product summary:

Package - Contents - Shelf Life: Ampoule, glass, 1 x 3 mL - 3 mL - 60 months from date of manufacture stored at or below 25°C - Combination pack, 1 x ( powder + diluent ) - 200 mg - 36 months from date of manufacture stored at or below 25°C 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) - Vial, glass, 1 x 200 mg - 200 mg - 36 months from date of manufacture stored at or below 25°C

Authorization date:

1991-08-27

Patient Information leaflet

TARGOCID®
1
TARGOCID
®
CONSUMER MEDICINE INFORMATION (CMI) SUMMARY
The full CMI on the next page has more details. If you are worried
about using this medicine, speak to your doctor or
pharmacist.
1.
WHY AM I BEING GIVEN TARGOCID?
Targocid contains the active ingredient teicoplanin. Targocid
injection is an antibiotic. It is used to kill bacteria responsible
for
infections which can occur in your blood, bones or joints. For more
information, see Section 1. Why am I being given Targocid?
in the full CMI.
2.
WHAT SHOULD I KNOW BEFORE I AM GIVEN TARGOCID?
Do not use if you have ever had an allergic reaction to Targocid or
any of the ingredients listed at the end of the CMI. TALK TO
YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER
MEDICINES, ARE PREGNANT OR PLAN TO BECOME PREGNANT,
OR ARE BREASTFEEDING OR PLANNING TO BREASTFEED. For more information,
see Section 2. What should I know before I am given
Targocid? in the full CMI. What if I am taking other medicines?
3.
WHAT IF I AM TAKING OTHER MEDICINES?
Some medicines may interfere with Targocid and affect how it works. A
list of these medicines is in Section 3. What if I am
taking other medicines? in the full CMI.
4.
HOW WILL I BE GIVEN TARGOCID?
•
Targocid injection should be prepared and administered by a qualified
health professional (doctor, pharmacist or nurse).
More instructions can be found in Section 4. How will I be given
Targocid? in the full CMI.
5.
WHAT SHOULD I KNOW WHILE BEING GIVEN TARGOCID?
THINGS YOU
SHOULD DO
•
Call your doctor straight away if you notice any symptoms of serious
skin reactions, including
blistering of your skin, mouth, eyes or genitals, a red scaly
widespread rash and blisters
accompanied by a fever, or flu-like symptoms and a rash on your face
and body with a fever.
•
Remind any doctor, dentist or pharmacist that you visit that you are
being given Targocid.
THINGS YOU
SHOULD NOT DO
•
Do not receive more than the recommended dose unless your doctor or
pharmacist tells you to.
•
Do not stop receiving

Summary of Product characteristics

targocid-ccdsv5-dsv9-03mar23
1
NEW ZEALAND DATA SHEET
1
PRODUCT NAME
Targocid 400 mg lyophilised powder for injection with water for
injections ampoule.
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains 400mg teicoplanin equivalent to not less than
400,000 IU.
For full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Teicoplanin lyophilised powder for injections is an off-white,
odourless powder contained in a
vial of 20 mL (400 mg) together with ampoules of water for injections.
The final solution is isotonic with plasma and has a pH of 7.2 -7.8.
See section 6.6.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Targocid is indicated in adults and in children from 2 months for the
treatment of the following
serious infections due to staphylococci or streptococci, which cannot
be treated satisfactorily with
less toxic agents including beta-lactam antibiotics:-
Bone - osteomyelitis
Joint - septic arthritis
Blood - non-cardiac bacteraemia, septicaemia
4.2
DOSE AND METHOD OF ADMINISTRATION
Teicoplanin can be administered either intravenously or
intramuscularly. Intravenous dosing may
be by rapid injection over 3-5 minutes, or more slowly over a 30
minute infusion. An
intramuscular injection of teicoplanin should not exceed 3 mL (400 mg)
at a single site. For
instructions on reconstitution of the medicine before administration
see Section 6.6.
Dosage is usually once daily following an initial loading dose which
is administered as three
12hourly doses on the first day of therapy. The dose is to be adjusted
on body weight whatever
the weight of the patient.
targocid-ccdsv5-dsv9-03mar23
2
The majority of patients with infections caused by organisms sensitive
to the antibiotic show a
therapeutic response within 48-72 hours. The total duration of therapy
is determined by the type
and severity of the infection and the clinical response of the
patient. The following periods are
often appropriate:
•
Uncomplicated bacteraemia 2-4 weeks
•
Septic arthritis or osteomyelitis 3-6 weeks
The use of teicopl